...
search icon
rapt-img

RAPT Therapeutics Inc, Common Stock

RAPT

NMQ

$0.8581

-$0.03

(-3.38%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$107.01M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
526.91K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
-0.04
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$0.71 L
$4.6 H
$0.8581

About RAPT Therapeutics Inc, Common Stock

RAPT Therapeutics, Inc. operates as a clinical-stage immunology-based biopharmaceutical company that focuses on the discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameRAPTSectorS&P500
1-Week Return6.07%0.86%-1.29%
1-Month Return4.52%-2.58%10.63%
3-Month Return-27.28%-10.87%-2.43%
6-Month Return-20.55%-8.73%-2.14%
1-Year Return-81.47%-10.19%10%
3-Year Return-93.17%0.5%46.86%
5-Year Return-95.23%32.08%97.3%
10-Year Return-93.4%75.49%174.39%

Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue5.04M3.81M1.53M--[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":75.62,"profit":true},{"date":"2022-12-31","value":30.29,"profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Cost of Revenue-996.00K2.81M3.55M-[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":28.05,"profit":true},{"date":"2022-12-31","value":79.05,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Gross Profit5.04M3.81M1.53M(3.55M)-[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":75.62,"profit":true},{"date":"2022-12-31","value":30.29,"profit":true},{"date":"2023-12-31","value":-70.43,"profit":false},{"date":"2024-12-31","value":"-","profit":true}]
Gross Margin100.00%100.00%100.00%--[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Operating Expenses58.26M73.02M87.32M127.06M136.10M[{"date":"2020-12-31","value":42.8,"profit":true},{"date":"2021-12-31","value":53.65,"profit":true},{"date":"2022-12-31","value":64.16,"profit":true},{"date":"2023-12-31","value":93.36,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Operating Income(53.21M)(69.21M)(85.80M)(127.06M)(136.10M)[{"date":"2020-12-31","value":-5321400000,"profit":false},{"date":"2021-12-31","value":-6920900000,"profit":false},{"date":"2022-12-31","value":-8579500000,"profit":false},{"date":"2023-12-31","value":-12706200000,"profit":false},{"date":"2024-12-31","value":-13610100000,"profit":false}]
Total Non-Operating Income/Expense-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Pre-Tax Income(51.90M)(69.20M)(83.84M)(116.80M)(129.87M)[{"date":"2020-12-31","value":-5190200000,"profit":false},{"date":"2021-12-31","value":-6920400000,"profit":false},{"date":"2022-12-31","value":-8383800000,"profit":false},{"date":"2023-12-31","value":-11679800000,"profit":false},{"date":"2024-12-31","value":-12986500000,"profit":false}]
Income Taxes990.00K(996.00K)(1.96M)--[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-100.61,"profit":false},{"date":"2022-12-31","value":-197.68,"profit":false},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Income After Taxes-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Income From Continuous Operations(52.89M)(69.20M)(83.84M)(108.87M)(129.87M)[{"date":"2020-12-31","value":-5289200000,"profit":false},{"date":"2021-12-31","value":-6920400000,"profit":false},{"date":"2022-12-31","value":-8383800000,"profit":false},{"date":"2023-12-31","value":-10887300000,"profit":false},{"date":"2024-12-31","value":-12986500000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(52.89M)(68.21M)(81.88M)(116.80M)(129.87M)[{"date":"2020-12-31","value":-5289200000,"profit":false},{"date":"2021-12-31","value":-6820800000,"profit":false},{"date":"2022-12-31","value":-8188100000,"profit":false},{"date":"2023-12-31","value":-11679800000,"profit":false},{"date":"2024-12-31","value":-12986500000,"profit":false}]
EPS (Diluted)(2.19)(2.53)(2.58)(3.04)(3.19)[{"date":"2020-12-31","value":-219,"profit":false},{"date":"2021-12-31","value":-253,"profit":false},{"date":"2022-12-31","value":-258,"profit":false},{"date":"2023-12-31","value":-304,"profit":false},{"date":"2024-12-31","value":-319.38,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

RAPT
Cash Ratio 20.66
Current Ratio 21.11

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

RAPT
ROA (LTM) -44.72%
ROE (LTM) -75.60%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

RAPT
Debt Ratio Lower is generally better. Negative is bad. 0.05
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.95

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

RAPT
Trailing PE NM
Forward PE NM
P/S (TTM) 411.22
P/B 0.72
Price/FCF NM
EV/R 677.37
EV/Ebitda NM

FAQs

What is RAPT Therapeutics Inc share price today?

RAPT Therapeutics Inc (RAPT) share price today is $0.8581

Can Indians buy RAPT Therapeutics Inc shares?

Yes, Indians can buy shares of RAPT Therapeutics Inc (RAPT) on Vested. To buy RAPT Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in RAPT stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of RAPT Therapeutics Inc be purchased?

Yes, you can purchase fractional shares of RAPT Therapeutics Inc (RAPT) via the Vested app. You can start investing in RAPT Therapeutics Inc (RAPT) with a minimum investment of $1.

How to invest in RAPT Therapeutics Inc shares from India?

You can invest in shares of RAPT Therapeutics Inc (RAPT) via Vested in three simple steps:

  • Click on Sign Up or Invest in RAPT stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in RAPT Therapeutics Inc shares
What is RAPT Therapeutics Inc 52-week high and low stock price?

The 52-week high price of RAPT Therapeutics Inc (RAPT) is $4.6. The 52-week low price of RAPT Therapeutics Inc (RAPT) is $0.71.

What is RAPT Therapeutics Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of RAPT Therapeutics Inc (RAPT) is 0.72

What is the Market Cap of RAPT Therapeutics Inc?

The market capitalization of RAPT Therapeutics Inc (RAPT) is $107.01M

What is RAPT Therapeutics Inc’s stock symbol?

The stock symbol (or ticker) of RAPT Therapeutics Inc is RAPT

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top